Henk Schuring

Henk is the Chief Regulatory and Commercialization Officer. At this position, Henk plays a critical role in defining the regulatory pathway for marketing authorization development and clinical programs and support the Company as it advances toward commercialization. Henk oversees all regulatory and commercialization aspects surrounding the upcoming late-stage clinical trials in ALS and Huntington’s Diseases (HD). Henk is also be responsible for global marketing activities.

Henk Schuring is a pharmacist with over 25 years’ experience in the pharmaceutical industry for both medicinal products and medicinal devices at executive level. He is an experienced executive and has a proven track record as a result oriented rare disease leader and a creative strategic thinker. Henk has been working in industry at various positions in Quality Assurance, Regulatory Affairs and Commercial at both European and global level.

Henk started in pharmaceutical industry at NPBI (nowadays Fresenius) in QA & RA of sterile manufacturing hospital solutions and anything needed for blood banks. From 1995-April 199 Henk was a consultant in the field of RA and QA. In April 1999 Henk joined Genzyme in Regulatory Affairs. His last position was Head of Regulatory Strategy for EMEA (Europe, Middle East, Africa) and JAPAC (Japan and Asia-Pacific). In this role Henk was part of development & commercialization of various rare disease products for Genzyme and Sanofi Genzyme. Many of these products were first approvals of a treatment for rare diseases.

In Nov 2014, Henk became VP-Head rare Neurology at Sanofi Genzyme and responsible for the area of rare neurology, which was build around he Pompe franchise. In Feb 2017, he took responsibility for Rare Nephrology as Global Head of Rare Nephrological diseases, including Fabry franchise. In these roles he was responsible for driving growth and expansion Sanofi Genzyme’s presence in the therapeutic area. This role oversaw the global marketing and commercial support for products approved in development in close collaboration with countries. In addition, this role was charged with influencing the direction of science and business development for diseases in the therapeutic area to ensure long term sustainability.

Henk graduated as a PharmD from University of Groningen (Netherlands)